Download presentation
Presentation is loading. Please wait.
Published byFrederick Miles Modified over 9 years ago
1
Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP
2
The Difference? Album EP
3
Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma Oral Cavity Cancer is a Surgical Disease Use Radiation Postoperatively for Appropriate Patients
4
RT can be used as primary therapy for small (T1, T2) tumors of the oral cavity. Oral tongue Floor of Mouth Lip Best results are with a combination of external beam radiation and brachytherapy
5
Difficult getting enough dose to primary with brachytherapy while still delivering adequate dose to the regional nodes IJROBP 1990; 18:1287-92. Brachytherapy complications: soft tissue necrosis, osteonecrosis
6
Postoperative Radiation for Oral Cavity Squamous Cell Cancer Who needs postop RT? Definite Indications: 1) Positive Margins 2) Multiple Nodes 3) Extracapsular Extension
7
Postoperative Radiation for Oral Cavity Squamous Cell Cancer Who needs postop RT? Less certain indications: 1) Lymphovascular space invasion 2) Perineural spread 3) Single encapsulated node + 4) Thick tumors ( Tumors 3-9 mm: 44% node+, 7% local recurrence; >9 mm: 53% subclinical node+, 24% local recurrence Head Neck 2002: 24:513-20 ) 5) Surgeon Vibe
8
Postoperative Radiation for Oral Cavity Squamous Cell Cancer Why give radiation after surgery? RTOG 73-03: locally advanced H&N cancers: supraglottic larynx, hypopharynx, oral cavity and oropharynx Preop (50 Gy) vs Postop (60 Gy) Oral Cavity/oropharynx also had definitive RT arm (65-70 Gy) followed by surgery if residual cancer Head Neck Surg 1987;10:19-30
9
Postoperative Radiation for Oral Cavity Squamous Cell Cancer RTOG 73-03 277 patients Ten year follow-up Improved locoregional control in postoperative RT arm (65%) vs. preop RT (48%, p=0.04) Trend toward improved survival: 38% vs 33%, p=0.10) Surgical and radiation therapy complications “similar”. IJROBP 1991;20:21-8.
10
Postoperative Radiation for Oral Cavity Cancer: Radiation Dose RTOG 7303 established 60 Gy as postop RT dose MD Anderson performed prospective randomized trial evaluating RT dose for 240 patients with resected stage III/IV cancers of oral cavity, oropharynx, hypopharynx, larynx 180 cGy fractions Dose ranged from 52.2 Gy to 68.4 Gy IJROBP 1993; 26:3-11.
11
Postoperative Radiation for Oral Cavity Cancer: Radiation Dose Patients receiving <54 Gy had significantly higher failure rate. No dose response beyond 57.6 Gy except for patients with extracapsular nodal spread. +ECE needed at least 63 Gy “Clusters” of two or more of the following also predicted increased risk of failure and need for 63 Gy: oral cavity primary, positive/close margins, nerve invasion, >2 positive nodes, largest node >3 cm, treatment delay >6weeks, Zubrod performance status>2 Moderate to severe complications seen in 7.1%; more if RT dose >63 Gy Dose escalation above 63 Gy “does not appear to improve the therapeutic ratio”.
12
Postoperative Radiation for Oral Cavity Cancer: RT + Chemotherapy Two large randomized trials evaluating RT with or without cisplatin chemotherapy in high-risk resected head and neck squamous cell cancers. EORTC RTOG NEJM 2004; 350:1945-1952 NEJM 2004: 350:1937-1944 High risk features: >2 + nodes, +ECE, + margins (EORTC also included perineural spread and vascular tumor embolism)
13
Postoperative Radiation for Oral Cavity Cancer: RT + Chemotherapy Radiation dose: 60 Gy RTOG; 66 Gy EORTC Cisplatin 100 mg/m2 days 1, 22, 43 both 334 EORTC + 459 RTOG patients (793 total) 26-27% oral cavity primaries In combined analysis, only patients with +ECE and/or + margins benefited from addition of cisplatin Head Neck 2005; 27: 843-850
14
Postoperative Radiation for Oral Cavity Cancer: RT + Chemotherapy
16
What’s Next? RTOG 0234 evaluated postop chemoRT (cisplatin or docetaxel) + EGFR inhibitor cetuximab (Erbitux) This phase II study completed but results are pending
17
Get to Work!! Three-Way Tie for Last
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.